Two additional clinical trials are currently underway.
1 - A dose escalation open label studies on Chronic Kidney Disease (CKD– stages III and IV) at Thomas Jefferson University, Philadelphia, PA
2 - A randomized, double blind, placebo control, cross over design clinical study in CKD V (Dialysis Patients) at Downstate Medical Center (State University of New York) and Kings County Hospital in Brooklyn.
Details on these trials are available at www.clinicaltrials.gov.
Kibow Biotech has completed a limited, pilot-scale, double-blind, placebo-controlled, cross-over, six-month human clinical trial at 5 different sites in 4 different countries for its probiotic formulation, Renadyl™. See Advances in Therapy for published results.
Clinical trials provide rigorous, independent scientific validation, for consumers and healthcare professionals, that Renadyl™ helps maintain healthy kidney function.
Renadyl™ is a patented and proprietary probiotics dietary supplement that has been scientifically formulated and clinically tested. Renadyl™ metabolizes nitrogenous waste that has diffused from the bloodstream into the bowel. Nitrogenous wastes are utilized by Renadyl™ as nutrients. As probiotics grow and multiply, they consume more nitrogenous waste and therefore effectively help maintain healthy kidney function. The nitrogenous metabolites are eliminated as solid waste/fecal matter.
Note: The statements on this website and the products offered have not been evaluated by the US Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Contents herein are being provided solely for the purpose of information. If you are pregnant, do not take any of our products listed herein. Also, please consult your physician or a qualified medical professional prior to taking this or any other dietary supplements or if you feel you have uremic, metabolic or related health conditions.